Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $7.0752W HIGH $20.15
Volume
2.24 M
Value Traded
32.30 M
Short % Float
11.23%
+4.32%Week
-9.51%1 Month
+14.9%3 Month
+91.94%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.14 B
EPS (TTM)
-0.40
P/E Ratio
-
Ent. Value
2.37 B
Total Shares
128.46 M
Float Shares
126.00 M
Insiders
1.93%
Institutions
113.38%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
NEO Catalyst Timeline
Dated clinical, regulatory and corporate events for NeoGenomics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for NeoGenomics, Inc.
122Total events
2Upcoming
21Tier-1 (high impact)
2012 to 2026Coverage
Upcoming catalysts 2
TBD
T2Timing Guidance
Subscribe to view catalyst details
TBD
T2Reimbursement / Pricing
Subscribe to view catalyst details
Event history 50
▲Reimbursement / PricingPost-Market
CMS MolDX grants expanded Medicare coverage for RaDaR ST in immunotherapy monitoring of late-stage solid tumors
immunotherapy treatment response monitoring in patients with late-stage solid tumorssource ↗
▲Product LaunchPost-Market
Launch of PTEN IHC CDx companion diagnostic
prostate adenocarcinomasource ↗
●Reimbursement / PricingPost-Market
Submitted new RaDaR ST evidence to MolDx supporting Medicare reimbursement for a new indication
▼Equity OfferingCorporate
Proposed offering of $275 million convertible senior notes due 2032
●Debt Royalty FinancingCorporate
Completed $316 million private offering of 0.75% convertible senior notes due 2032
●Legal / SettlementCorporate
Finalized civil settlement with Department of Justice resolving self-disclosed matter
◆Poster PresentationPresentation
Eight scientific posters at AACR Annual Meeting 2026
oncologysource ↗
◆Oral PresentationPresentation
Participation in Leerink Partners Global Healthcare Conference 2026
▲Product LaunchPost-Market
Launch of RaDaR ST ctDNA assay for MRD detection
multiple solid tumor typessource ↗
▲Product LaunchPost-Market
NeoGenomics announces availability of PanTracer Pro
advanced-stage solid tumorssource ↗
▲Product LaunchPost-Market
Launched RaDaR ST ctDNA assay for MRD detection
molecular residual disease (MRD)source ↗
▲FDA Feedback ReceivedFDA Meeting
Favorable MolDX coverage decision for PanTracer LBx
advanced solid tumorssource ↗
◆Oral PresentationRaDaRPresentation
Presentation of new ctDNA data from SURVIVE HERoes Phase III trial at SABCS 2025
early breast cancersource ↗
▼Quarterly UpdateCorporate
Anticipates Q1 2022 revenue below guidance and EBITDA loss larger than expected
▼Equity OfferingCorporate
Pricing of public offerings of common stock and convertible senior notes
▼Equity OfferingCorporate
Pricing of common stock offering of 4,400,000 shares at $28.50 per share
▲Debt Royalty FinancingCorporate
New $250 million Senior Secured Credit Agreement entered into
▼Equity OfferingCorporate
Pricing of underwritten public offering of 7,000,000 shares at $21.25 per share
▼Equity OfferingCorporate
Pricing of secondary offering of 10,835,145 shares by selling stockholder
▼Equity OfferingCorporate
Secondary offering of 10,835,145 shares by selling stockholder GE Info Tech
▼Equity OfferingCorporate
Pricing of underwritten public offering of 9,800,000 shares at $12.75 per share
▲Partnership / LicenseCorporate
PPD and NeoGenomics form global strategic alliance for pathology and molecular testing solutions
oncologysource ↗
▲Quarterly UpdateCorporate
NeoGenomics reports Q4 2017 revenue of $67.8 million and adjusted EBITDA of $10.5 million
▼Quarterly UpdateCorporate
NeoGenomics anticipates lower pharma services revenue and gross margin in Q1 2018 vs Q4 2017
▲Manufacturing MilestoneCMC / Inspection
NeoGenomics opened new European lab facility in Rolle, Switzerland
●Quarterly UpdateCorporate
Issued preliminary Q4 2017 guidance: revenue $65-$67 million, Adjusted EBITDA $9-$10 million
Past FDA Catalysts and PDUFA Decisions
How NEO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
NeoGenomics, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every NEO program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Stone WarrenOfficer (Pres & Chief Operating Officer) | Option | 17,562 198,640 held | $0.00 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NEO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 0 % (-100 %) | 145.00 K | 10.00 K | -97.66% ( -417.50 K) |
NEO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NEO ranks across every disease it competes in
Competitive Position is a premium feature
See how NEO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNEO News
-NEO
Oct 14, 2026▲ +2.8%today
NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026
NeoGenomics has announced that it will release its financial results for the third quarter of 2026 on October 28, 2026. The report will be made available after the U.S. financial markets close. This announcement is part of the company's commitment to keeping stakeholders informed about its financial performance.
Read more →-NEO
Oct 5, 2026▼ -13.7%on this news
NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
NeoGenomics has revealed its succession plan for executive leadership and the board of directors. This strategic move aims to ensure continuity and strengthen governance within the company. The announcement reflects the company's commitment to effective leadership transition.
Read more →-NEO
Sep 1, 2026NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
NeoGenomics is set to participate in the Morgan Stanley 24th Annual Global Healthcare Conference scheduled for September 14-16, 2026, in New York. This event presents an opportunity for the company to highlight its innovations and engage with key stakeholders in the healthcare sector.
Read more →-NEO
Aug 26, 2026▲ +7.3%on this newsshared move
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
NeoGenomics has announced that its RaDaR ST minimal residual disease (MRD) assay has received expanded coverage under Medicare's MolDX program. This assay is designed for monitoring immunotherapy responses in patients with late-stage solid tumors, potentially improving patient management and treatment outcomes.
Read more →-NEO
Jul 28, 2026▲ +14%on this news
NeoGenomics Reports Second Quarter 2026 Results
NeoGenomics has reported its financial results for the second quarter of 2026, ending on June 30. The announcement was made from Fort Myers, Florida. Specific details regarding revenue, profit, or other financial metrics were not included in the provided text.
Read more →-NEO
Jul 20, 2026NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
NeoGenomics has announced a settlement regarding its voluntary disclosure to the Office of Inspector General for Health and Human Services (OIG-HHS). This settlement reflects the company's efforts to address compliance matters proactively. The announcement highlights NeoGenomics' commitment to maintaining regulatory standards.
Read more →-NEO
Jul 9, 2026NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
NeoGenomics has launched the PTEN IHC CDx, marking it as the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. FDA specifically for patients with prostate adenocarcinoma. This approval represents a significant step forward in the field of personalized medicine, aiming to enhance treatment strategies for prostate cancer patients.
Read more →-NEO
Jul 7, 2026NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026
NeoGenomics has announced the date for its second quarter 2026 financial results report, which is scheduled for July 28, 2026. The announcement is part of the company's regular financial reporting cycle. Further details regarding the financial performance will be provided at that time.
Read more →-NEO
Jun 25, 2026▲ +6.4%on this news
NeoGenomics Appoints Carolyn Starrett to its Board of Directors
NeoGenomics has appointed Carolyn Starrett to its Board of Directors. This decision is part of the company's ongoing efforts to enhance its leadership team. The appointment aims to bring valuable insights and experience to the board, although specific details regarding her role and contributions were not disclosed.
Read more →-NEO
Jun 17, 2026NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
NeoGenomics has announced the pricing of an offering of $275 million in convertible senior notes. This move is part of the company's financial strategy, although specific details about the intended use of proceeds or terms of the notes have not been disclosed.
Read more →-NEO
Jun 15, 2026NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes
NeoGenomics, Inc. has announced a proposed offering of $275 million in convertible senior notes due 2032, aimed at qualified institutional buyers. The company may grant purchasers an option to buy an additional $41.25 million in notes as part of the offering, subject to market conditions. Proceeds from the offering will be used for capped call transactions, repaying existing convertible notes, and repurchasing shares of common stock. However, the success of the offering depends on fluctuating market conditions, and there are no guarantees regarding its completion.
Read more →-NEO
May 26, 2026NeoGenomics to Present New Research at ASCO Annual Meeting 2026
NeoGenomics, Inc. announced its participation in the 2026 ASCO Annual Meeting, where it will present eight scientific abstracts focused on advancements in precision oncology and molecular residual disease. The presentations will cover various topics, including genomic profiling and the impact of insurance coverage on next-generation sequencing. The company aims to enhance personalized cancer treatment through innovative diagnostics.
Read more →-NEO
Apr 29, 2026NeoGenomics Reports First Quarter 2026 Results
NeoGenomics reported a strong first quarter for 2026, with total revenue rising 11% year-over-year to $187 million. The company also saw a 14% increase in clinical revenue, driven by a 26% growth in next-generation sequencing (NGS). Additionally, NeoGenomics raised its full-year revenue guidance to between $797 million and $803 million, reflecting confidence in its growth strategy.
Read more →-NEO
Apr 13, 2026NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026
NeoGenomics, a leader in oncology diagnostics, will present eight scientific posters and one oral presentation at the AACR Annual Meeting 2026 in San Diego. The research emphasizes the importance of combining laboratory testing with clinical data to drive advancements in oncology. CEO Tony Zook highlighted the company's collaborations with biopharma partners, showcasing how these insights can enhance therapy development.
Read more →-NEO
Feb 26, 2026NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
NeoGenomics has launched RaDaR ST, a new ctDNA assay for detecting molecular residual disease (MRD) across various solid tumor types. This innovative test aims to provide earlier detection of cancer recurrence, supporting better clinical decisions. The assay is validated through extensive clinical data and is approved by Medicare for initial indications.
Read more →-NEO
Feb 18, 2026▼ -10.3%on this news
NeoGenomics to Participate in Upcoming March 2026 Investor Conferences
NeoGenomics, Inc. has announced its participation in several investor conferences scheduled for March 2026. The company, known for its oncology diagnostic solutions, aims to enhance investor engagement and showcase its innovative services. Live and archived webcasts of the sessions will be available on its Investor Relations website.
Read more →-NEO
Feb 17, 2026NeoGenomics Reports Fourth Quarter and Full Year 2025 Results
NeoGenomics reported a strong financial performance for Q4 and full-year 2025, with a 10% increase in revenue to $727 million. The company highlighted significant growth in clinical revenue and successful resolution of patent litigation. However, they also faced a net loss of $108 million for the year, attributed to lower non-clinical revenue and increased operating expenses. Looking ahead, the launch of the RaDaR ST MRD assay is expected to enhance their offerings in the molecular residual disease monitoring market.
Read more →-NEO
Feb 12, 2026NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection
NeoGenomics has launched PanTracer Pro, a new testing solution designed to assist clinicians in making informed decisions for patients with advanced-stage solid tumors. This integrated approach aims to streamline the diagnostic process by providing earlier biomarker insights and reducing uncertainty in complex cases. The test offers a turnaround time of 8-10 days, facilitating timely treatment planning.
Read more →-NEO
Jan 27, 2026NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
NeoGenomics, Inc. will announce its fourth quarter and full year 2025 financial results on February 17, 2026. The results will be shared prior to the U.S. market opening, followed by a conference call at 8:30 a.m. ET. The company provides a comprehensive range of oncology diagnostic solutions.
Read more →-NEO
Jan 5, 2026NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
NeoGenomics, Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. The company's management is set to present and engage in a Q&A session on January 13. This event provides a platform for NeoGenomics to highlight its oncology diagnostic solutions and connect with investors.
Read more →About NeoGenomics, Inc.
Headquarters9490 NEOGENOMICS WAY, FORT MYERS, FL, 33912
BIOPHARMAWATCH ELITE PLUS
Trade the next NEO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime